scholarly journals Clinical correlation with pathology of placenta in medical disorders of pregnancy and its comparison in normal pregnancy

2016 ◽  
Vol 6 (1) ◽  
pp. 127
Author(s):  
Ratnamala Siddheshware ◽  
Sunil S. Patil ◽  
Pradip W. Sambarey
Keyword(s):  
Diabetes Mellitus ◽  
Heart Disease ◽  
Normal Pregnancy ◽  
Hypertensive Disorder ◽  
Foetal Development ◽  
Medical Disorders ◽  
High Incidence ◽  
Microscopic Change ◽  
Fibrinoid Degeneration ◽  
Morbid Conditions

Background: Healthy placenta is responsible for maintaining pregnancy and promoting normal foetal development. It reflects the intrauterine status of the foetus.Methods: In the present prospective study, total 50 Placentae from Medical Disorders of Pregnancies were studied and compared with equal number of Placentae from normal Pregnancies.Results: The significant macroscopic changes were calcification and infarction seen in Hypertensive Disorder. Extensive placental infarction was associated with high incidence of low APGAR (82%) and perinatal deaths (66.67%). No significant gross macroscopic changes were seen in Anaemia, Diabetes Mellitus and Heart Disease. Increased syncytial knots, fibrinoid degeneration, vasculo-syncytial membrane paucity were significant microscopic changes in Hypertensive Disorder. In Anaemia stromal fibrosis, increased syncytial knots were seen, whereas in Diabetes Mellitus villous edema was the most significant microscopic finding. No significant microscopic change was found in Heart Disease. Increased syncytial knots, fibrinoid degeneration, vasculo-syncytial membrane paucity, stromal fibrosis were associated with increased perinatal mortality.Conclusions: Gross and microscopic examination of placenta is strongly recommended in cases where maternal co-morbid conditions is likely to have an adverse perinatal outcome.

scholarly journals Medical co-morbid conditions associated with psoriasis; psoriasis beyond skin.

2020 ◽  
Vol 27 (03) ◽  
pp. 511-516
Author(s):  
Sehrish Aftab ◽  
Mahvish Aftab Khan ◽  
Nadia x Nadia Shams ◽  
Sumaira x Sumaira Abdullah ◽  
Furquana Niaz
Keyword(s):  
Diabetes Mellitus ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Ischemic Heart ◽  
Cross Sectional ◽  
Dermatology Department ◽  
Female Ratio ◽  
Dermatology Clinic ◽  
Medical Disorders ◽  
Morbid Conditions

Objectives: Patients with psoriasis have higher prevalence of associated medical disorders including psoriatic arthritis, obesity, diabetes, dyslipidemia, thyroid abnormalities and cardiovascular disease. The rationale of current study was to determine prevalence of associated medical co-morbid conditions in psoriasis cases. Study Design: Descriptive cross sectional study. Setting: Dermatology Clinic, Bahawalpur Victoria Hospital. Period: January to July 2015. Material & Methods: Informed consent was obtained from 117 adult patients (>18 years) of both the genders diagnosed with psoriasis for >3 months. Patients with chronic renal failure, chronic liver disease, erythroderma, chromosomal abnormality syndromes and pregnant females were excluded. Blood pressure and body mass index; i.e. BMI=weight (kg)/ height (m2) were documented. Fasting blood sugars, HbA1c, lipid profile and electrocardiogram was done. Results: Mean age was 41.94±11.60 years. Among 117 cases, 66(56.41%) were males and 51(43.59%) were females; male to female ratio was 1.3:1. Diabetes mellitus was found in 53(45.30%), hypertension in 21(17.95%), obesity in 29(24.79%), ischemic heart disease in 62(52.99%) and dyslipidemia in 22(18.80%) patients. Conclusion: Current study concludes that patients with psoriasis have higher prevalence of ischemic heart disease and diabetes mellitus followed by obesity, dyslipidemia and hypertension. It is suggested that psoriasis cases presenting to dermatology department should be assessed for these co-morbid conditions for early diagnosis and management of these conditions.

Metabolic syndrome, diabetes mellitus, and the subsequent development of prostate cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 5158-5158
Author(s):  
Y. R. Lawrence ◽  
O. Morag ◽  
V. Boyko ◽  
M. Benderly ◽  
U. Goldbourt ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Diabetes Mellitus ◽  
Metabolic Syndrome ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Subsequent Development ◽  
Ischemic Heart ◽  
Bezafibrate Infarction Prevention ◽  
Medical Disorders

5158 Background: The lifetime risk of an American man developing prostate cancer (PC) is one in six. Metabolic syndrome (MS) is a cluster of medical disorders (hypertension, dyslipidaemia, hyperglycaemia, obesity) associated with the subsequent development of diabetes mellitus (DM). DM and MS afflict 11% and 22% of US adults respectively. MS and DM are associated with disturbed lipid homeostasis, and hypogonadism. DM and MS predispose to the development of gastrointestinal and endometrial cancer. DM and MS's influence on PC is less clear; some studies have suggested that whereas DM inhibits PC, MS promotes PC development. Methods: The Bezafibrate Infarction Prevention study was a randomized trial of fibrate therapy for the secondary prevention of ischemic heart disease. Between 1990–2 15524 men and women with ischemic heart disease were screened, of whom 3090 entered the trial. 81% were male. Participants were divided into three groups according to baseline parameters: (A) those with neither MS nor DM, (B) those with MS but no DM, (C) those with DM (with or without MS). MS was defined according to ATPIII guidelines. DM was defined by medical history or fasting glucose > 125 mg/dL. Follow-up for PC incidence and all-cause mortality was obtained through the Israeli cancer registry and the Ministry of the Interior respectively. Analysis accounts for differences in age and non-cancer-related-mortality between groups. Ethics approval was obtained. Results: 1350 participants were excluded due to missing data or previous cancer diagnosis, leaving 11,541 men. Mean age at enrollment 61 years (45–74). Median follow-up was 12 years. There were 6119 (53%), 3,376 (29%), and 2,046 (18%) participants in groups A, B and C respectively. Overall there were 459 cases of PC; 298, 123 and 48 in groups A, B and C. The age adjusted PC rates were 4.30, 3.61 and 2.55 per 1,000 patient years in groups A, B and C respectively (A vs C p = 0.003). Data were also analyzed examining PC incidence as a function of ‘number of components of MS present’ after pooling groups A, B and C. Relative risk of developing PC was 1.00, 0.92, 0.90, 0.69, 0.71, and 0.33 for 0, 1, 2, 3, 4, and 5 components respectively. Conclusions: A baseline diagnosis of DM (highly significant) or MS (trend) was associated with a decreased prostate cancer rate over the subsequent 12 years. No significant financial relationships to disclose.

Mutations of mtDNA in some vascular and metabolic diseases

2020 ◽  
Vol 26 ◽  
Author(s):  
Margarita A. Sazonova ◽  
Anastasia I. Ryzhkova ◽  
Vasily V. Sinyov ◽  
Marina D. Sazonova ◽  
Tatiana V. Kirichenko ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Coronary Heart Disease ◽  
Type 2 Diabetes Mellitus ◽  
Heart Disease ◽  
Chronic Diseases ◽  
Metabolic Diseases ◽  
Present Review ◽  
Mtdna Mutations

Background: The present review article considers some chronic diseases of vascular and metabolic genesis, the causes of which may be mitochondrial dysfunction. Very often, in the long course of the disease, complications may occur, leading to myocardial infarction or ischemic stroke and as a result, death.In particular, a large percentage of human deaths nowadays belongs to cardiovascular diseases such as coronary heart disease (CHD), arterial hypertension, cardiomyopathies and type 2 diabetes mellitus. Objective: The aim of the present review was the analysis of literature sources, devoted to an investigation of a link of mitochondrial DNA mutations with chronic diseases of vascular and metabolic genesis, Results: The analysis of literature indicates the association of the mitochondrial genome mutations with coronary heart disease, type 2 diabetes mellitus, hypertension and various types of cardiomyopathies. Conclusion: The detected mutations can be used to analyze the predisposition to chronic diseases of vascular and metabolic genesis. They can also be used to create molecular-cell models necessary to evaluate the effectiveness of drugs developed for treatment of these pathologies. MtDNA mutations associated withthe absence of diseases of vascular and metabolic genesis could be potential candidates for gene therapy of diseases of vascular and metabolic genesis.

Sign in / Sign up

Export Citation Format

Share Document